Research programme: allogeneic super natural killer cell therapies - NKGen Biotech

Alternative Names: Allogeneic SNK therapies - NKGen Biotech

Latest Information Update: 21 Jul 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NKGen Biotech
Class Gene therapies; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

19 Jul 2021 Research programme: allogeneic super natural killer cell therapies - NKGen Biotech is available for licensing as of 19 Jul 2021. https://nkgenbiotech.com/our-partnerships/
16 Jul 2021 Preclinical trials in Unspecified in USA (Parenteral) (NKGen Biotech Website, July 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com